Response to crizotinib in a lung adenocarcinoma patient harboring a novel SLC34A2-ROS1 fusion variant

Response to crizotinib in a lung adenocarcinoma patient harboring a novel SLC34A2-ROS1 fusion variant

Zheng Zhao,1 Zhangjun Song,2 Xuwei Wang,3 Haifeng Sun,1 Xiaomin Yang,2 Yong Yuan,4 Pan Yu3 1Third Department of Medical Oncology, Shannxi Provincial Cancer Hospital, 2Breast Surgery Center, Shannxi Provincial Cancer Hospital, Xi’an, 3Marketing Department, Novogene Bioinformatics Institute...

Full description

Bibliographic Details
Main Authors: Zhao Z, Song ZJ, Wang XW, Sun HF, Yang XM, Yuan Y, Yu P
Format: Article
Language:English
Published: Dove Medical Press 2017-08-01
Series:OncoTargets and Therapy
Subjects:
SLC34A2-ROS1 fusion
crizotinib
lung adenocarcinoma
next-generation sequencing
Online Access:https://www.dovepress.com/response-to-crizotinib-in-a-lung-adenocarcinoma-patient-harboring-a-no-peer-reviewed-article-OTT

Internet

https://www.dovepress.com/response-to-crizotinib-in-a-lung-adenocarcinoma-patient-harboring-a-no-peer-reviewed-article-OTT

Similar Items